SBIR/STTR Research Award
MOLECULAR PROBES FOR BURKITT'S AND MANTLE CELL LYMPHOMA
Award amount
$158,425Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Gentris Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
APPLICANT?S DESCRIPTION: The goal of this research is to develop two
fluorescence in situ hybridization (FISH) assays for the detection of the
t(11;14)(q13;q32) and the t(8;14)(q24;q32) chromosomal translocations
encountered in Mantle and Burkitt?s B-cell Lymphoma respectively. These tumors
are traditionally treated by radiation and chemotherapy; however many patients
relapse and become refractory to treatment. Diagnosis and post-treatment
follow-up are performed by flow cytometry, karyotype, Southern Blotting, or
PCR, each of which has limitations of specificity and/or sensitivity.
Therefore, another precise, reliable, and easy method to detect tumor cells
especially in the post-treatment specimens is essential. Such a method is FISH.
Unfortunately, no clinically tested probes are available for the detection of
either Mantle or Burkitt?s Lymphoma. In this Phase I application, we propose to
develop BAC-based probes to detect translocation carrying nuclei in diagnostic
and follow up patient samples. The probes for each chromosome will be labeled
with a different color and will unambiguously identify the two normal and the
two rearranged chromosomes in each nucleus, thereby providing high specificity
and sensitivity.
PROPOSED COMMERCIAL APPLICATION:
The proposed research will provide FISH assays to detect the t(11;14)(q13;q32) and
t(8;14)(q24;q32) chromosomal translocations encountered in Mantle Cell Lymphoma and
Burkitt's Lymphoma, respectively, for use in cancer cytogenetic reference laboratories.
Technology keywords
Not reported